Journal article
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
Leukemia & lymphoma, Vol.46(11), pp.1569-1573
2005
DOI: 10.1080/10428190500217312
PMID: 16236611
Abstract
The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL). Thirty-three patients with previously untreated aggressive B-cell NHL received six infusions of rituximab (375 mg m2 per dose) on day 1 of each cycle of CHOP chemotherapy, given on day 3 of each cycle of therapy. Currently, the patients now have a median follow-up of 63 months (range 34 - 82 months). The overall response (OR) rate was 94% and the complete response (CR) rate was 61% at the end of therapy. Of the 33 patients, 2 patients experienced disease progression and subsequently died of their disease, 2 patients experienced disease progression but were alive at last follow-up following additional therapy, and 2 patients died without experiencing disease progression: one due to a cerebral vascular accident at 9 months after therapy and a second patient due to small cell lung carcinoma at 55 months. The 5-year survival rate was 88% (95% confidence interval (CI) 72 - 97) and the 5-year progression-free survival was 82% (95% CI 64 - 93). There were no long-term adverse events noted directly related to the rituximab. The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.
Details
- Title: Subtitle
- Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
- Creators
- J. M Vose - 1University of Nebraska Medical Center, Omaha, NE, USAB. K Link - 2University of Iowa, Iowa City, IA, USAM. L Grossbard - 3St Luke's Roosevelt Hospital, New York, NY, USAM Czuczman - 4Roswell Park Cancer Institute, Buffalo, NY, USAA Grillo-Lopez - 5Neoplastic and Autoimmune Disease Research Institute, Rancho Santa Fe, CA, USAR. I Fisher - 6James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
- Resource Type
- Journal article
- Publication Details
- Leukemia & lymphoma, Vol.46(11), pp.1569-1573
- Publisher
- Informa UK Ltd
- DOI
- 10.1080/10428190500217312
- PMID
- 16236611
- ISSN
- 1042-8194
- eISSN
- 1029-2403
- Language
- English
- Date published
- 2005
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094549902771
Metrics
26 Record Views